Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Infect Drug Resist. 2010;3:123-32. doi: 10.2147/IDR.S7838. Epub 2010 Oct 28.

Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis.

Author information

  • 1Spectrum Health, Grand Rapids, Michigan;

Abstract

Progressive obstructive lung disease is a characteristic component of cystic fibrosis (CF). It is the pulmonary manifestations, including obstruction and endobronchial infection, which directly contribute to the premature mortality of patients affected with CF. Due to the devastating effects on the pulmonary system, interest abounds in ways to improve antimicrobial delivery to the lungs and to impact clinical patient outcomes positively, whilst minimizing systemic toxicities. Recently, aztreonam lysine for inhalation solution, a new monobactam formulation, was approved by the US Food and Drug Administration for use in a subgroup of CF patients with Pseudomonas aeruginosa to improve respiratory symptoms. The purpose of this review is to present a summary of relevant pharmacologic, microbiologic, and clinical data related to the use of aztreonam lysine for inhalation in patients with CF.

KEYWORDS:

Pseudomonas aeruginosa; aerosolized; antibiotic; aztreonam; cystic fibrosis; inhaled

PMID:
21694901
[PubMed]
PMCID:
PMC3108734
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk